Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2007

InterMune Achieves $10M Milestone from Roche

  • InterMune received $10-million upon completion of a large-scale synthesis of the active pharmaceutical ingredient in Roche’s hepatitis C virus (HCV) drug candidate. ITMN-191 is currently in a Phase Ia trial.

    This milestone is part of the companies' collaboration to develop and commercialize novel protease inhibitors for the treatment of HCV. 

    "InterMune has successfully executed key steps in the manufacture of a sophisticated protease inhibitor molecule and transferred the materials to Roche for future studies," says Lawrence M. Blatt, Ph.D., CSO of InterMune.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »